These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical evaluation of panipenem/betamipron as a second line chemotherapy in severe infections associated with hematological disorders].
    Author: Nakazawa N, Okamoto T, Kobayashi M, Iwai T, Sasai Y, Tamura A, Horiike S, Yokota S, Taniwaki M, Kashima K, Misawa S, Tuda S, Ohkawara Y.
    Journal: Jpn J Antibiot; 1998 Aug; 51(8):509-20. PubMed ID: 9836123.
    Abstract:
    Thirty three patients with severe infections associated with hematological disorders were treated with panipenem/betamipron as a second line chemotherapy. Of these, 30 patients were evaluated for effectiveness. An excellent response was obtained in 14 patients (46.7%) and a good response in 5 (16.7%), and the overall efficacy rate was 63.3%. Efficacy rates were 3/6 in patients with sepsis, 68.4% (13/19) in patients with fever of undetermined origin, 2/4 in patients with pneumonia. In patients whose peripheral granulocyte count was below 100/microliter at the start of chemotherapy, the efficacy rate was 3/7. Side effects were observed in 5 of 33 patients (15.2%). These results show that PAPM/BP is useful as a second line chemotherapy for the treatment of severe infections in patients with hematological disorders.
    [Abstract] [Full Text] [Related] [New Search]